

# John D Fisk

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8862389/john-d-fisk-publications-by-citations.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

197  
papers

10,812  
citations

50  
h-index

100  
g-index

212  
ext. papers

12,457  
ext. citations

3.9  
avg, IF

6.25  
L-index

#	Paper	IF	Citations
197	The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. <i>Arthritis and Rheumatism</i> , <b>1999</b> , 42, 599-608		1533
196	Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. <i>Clinical Infectious Diseases</i> , <b>1994</b> , 18 Suppl 1, S79-83	11.6	945
195	The Impact of Fatigue on Patients with Multiple Sclerosis. <i>Canadian Journal of Neurological Sciences</i> , <b>1994</b> , 21, 9-14	1	714
194	Minimal neuropsychological assessment of MS patients: a consensus approach. <i>Clinical Neuropsychologist</i> , <b>2002</b> , 16, 381-97	4.4	459
193	The risk of dementia and death after delirium. <i>Age and Ageing</i> , <b>1999</b> , 28, 551-6	3	291
192	Incidence and prevalence of multiple sclerosis in Europe: a systematic review. <i>BMC Neurology</i> , <b>2013</b> , 13, 128	3.1	289
191	The organization of eye and limb movements during unrestricted reaching to targets in contralateral and ipsilateral visual space. <i>Experimental Brain Research</i> , <b>1985</b> , 60, 159-78	2.3	242
190	Variations in case definition affect prevalence but not outcomes of mild cognitive impairment. <i>Neurology</i> , <b>2003</b> , 61, 1179-84	6.5	213
189	A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>1999</b> , 42, 728-34		190
188	Five-year follow-up of cognitive impairment with no dementia. <i>Archives of Neurology</i> , <b>2003</b> , 60, 577-82		171
187	Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients. <i>Pain</i> , <b>1994</b> , 58, 89-98		160
186	A comparison of health utility measures for the evaluation of multiple sclerosis treatments. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2005</b> , 76, 58-63	5.5	146
185	Incidence and prevalence of multiple sclerosis in the Americas: a systematic review. <i>Neuroepidemiology</i> , <b>2013</b> , 40, 195-210	5.4	138
184	Information processing efficiency in patients with multiple sclerosis. <i>Journal of Clinical and Experimental Neuropsychology</i> , <b>2000</b> , 22, 686-701	2.1	127
183	Neuropsychological predictors of incident dementia in patients with vascular cognitive impairment, without dementia. <i>Stroke</i> , <b>2002</b> , 33, 1999-2002	6.7	116
182	Diffusion tensor imaging and olfactory identification testing in early-stage Parkinson's disease. <i>Journal of Neurology</i> , <b>2011</b> , 258, 1254-60	5.5	115
181	Health-related quality of life in multiple sclerosis: Direct and indirect effects of comorbidity. <i>Neurology</i> , <b>2016</b> , 86, 1417-1424	6.5	110

180	Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. <i>Cmaj</i> , <b>2008</b> , 179, 1019-26	3.5	104
179	Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia. <i>Multiple Sclerosis Journal</i> , <b>2012</b> , 18, 1310-9	5	97
178	Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2006</b> , 33, 1553-8	4.1	97
177	Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance. <i>BMC Neurology</i> , <b>2013</b> , 13, 16	3.1	96
176	Psychiatric comorbidity is associated with disability progression in multiple sclerosis. <i>Neurology</i> , <b>2018</b> , 90, e1316-e1323	6.5	95
175	Construction and validation of a fatigue impact scale for daily administration (D-FIS). <i>Quality of Life Research</i> , <b>2002</b> , 11, 263-72	3.7	95
174	Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2016</b> , 5, 12-26	4	93
173	Limitations of the Paced Auditory Serial Addition Test as a measure of working memory in patients with multiple sclerosis. <i>Journal of the International Neuropsychological Society</i> , <b>2001</b> , 7, 363-72	3.1	89
172	Increased Burden of Psychiatric Disorders in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 360-368	4.5	87
171	Increased incidence of psychiatric disorders in immune-mediated inflammatory disease. <i>Journal of Psychosomatic Research</i> , <b>2017</b> , 101, 17-23	4.1	86
170	Cognitive function in systemic lupus erythematosus: results of a 5-year prospective study. <i>Arthritis and Rheumatism</i> , <b>1997</b> , 40, 1542-3		84
169	Neuropsychological testing and assessment for dementia. <i>Alzheimeris and Dementia</i> , <b>2007</b> , 3, 299-317	1.2	84
168	High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991-2010). <i>Journal of Neurology</i> , <b>2015</b> , 262, 2352-63	5.5	83
167	Gravitoinertial force level influences arm movement control. <i>Journal of Neurophysiology</i> , <b>1993</b> , 69, 504-13	1.2	83
166	Differences in the burden of psychiatric comorbidity in MS vs the general population. <i>Neurology</i> , <b>2015</b> , 85, 1972-9	6.5	81
165	Societal costs of vascular cognitive impairment in older adults. <i>Stroke</i> , <b>2002</b> , 33, 1605-9	6.7	79
164	Short term predictors of unemployment in multiple sclerosis patients. <i>Canadian Journal of Neurological Sciences</i> , <b>2003</b> , 30, 137-42	1	78
163	Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study. <i>Lancet Neurology</i> , <b>2017</b> , 16, 445-451	24.1	74

162	The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2018</b> , 20, 9-15	4	69
161	Longitudinal changes in microstructural white matter metrics in Alzheimer's disease. <i>NeuroImage: Clinical</i> , <b>2017</b> , 13, 330-338	5.3	68
160	Functional competence of community-dwelling persons with multiple sclerosis using the assessment of motor and process skills. <i>Archives of Physical Medicine and Rehabilitation</i> , <b>1994</b> , 75, 843-51 <sup>2.8</sup>	2.8	66
159	Neuropsychiatric syndromes in patients with systemic lupus erythematosus and rheumatoid arthritis. <i>Journal of Rheumatology</i> , <b>2005</b> , 32, 1459-6	4.1	66
158	Increased Burden of Psychiatric Disorders in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 970-978	4.7	64
157	Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. <i>Neurology</i> , <b>2016</b> , 86, 1287-1295	6.5	63
156	How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?. <i>Neurology</i> , <b>2007</b> , 69, 1498-507	6.5	62
155	Sex differences in comorbidity at diagnosis of multiple sclerosis: A population-based study. <i>Neurology</i> , <b>2016</b> , 86, 1279-1286	6.5	61
154	Factors influencing healthy aging with multiple sclerosis: a qualitative study. <i>Disability and Rehabilitation</i> , <b>2012</b> , 34, 26-33	2.4	56
153	Diagnosis and treatment of dementia: 4. Approach to management of mild to moderate dementia. <i>Cmaj</i> , <b>2008</b> , 179, 787-93	3.5	56
152	Assessment of cognitive function in systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis by computerized neuropsychological tests. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 1478-86		53
151	Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders. <i>Neurology</i> , <b>2019</b> ,	6.5	52
150	Infection-related health care utilization among people with and without multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 1506-1516	5	51
149	The Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , <b>2018</b> , 24, 1867-1875	4.5	50
148	Psychological well-being in relation to frailty: a frailty identity crisis?. <i>International Psychogeriatrics</i> , <b>2012</b> , 24, 1347-53	3.4	50
147	The utility of administrative data for surveillance of comorbidity in multiple sclerosis: a validation study. <i>Neuroepidemiology</i> , <b>2013</b> , 40, 85-92	5.4	49
146	Comorbidity increases the risk of relapse in multiple sclerosis: A prospective study. <i>Neurology</i> , <b>2017</b> , 89, 2455-2461	6.5	45
145	The Incidence and Prevalence of Multiple Sclerosis in Nova Scotia, Canada. <i>Canadian Journal of Neurological Sciences</i> , <b>2013</b> , 40, 824-831	1	44

144	Relationship Between DTI Metrics and Cognitive Function in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , <b>2018</b> , 10, 436	5.3	42
143	Effects of physical comorbidities on disability progression in multiple sclerosis. <i>Neurology</i> , <b>2018</b> , 90, e418-427	4.2	42
142	Measuring functional competence in older persons with Alzheimer's disease. <i>International Psychogeriatrics</i> , <b>1997</b> , 9, 25-38	3.4	40
141	Psychiatric comorbidity increases mortality in immune-mediated inflammatory diseases. <i>General Hospital Psychiatry</i> , <b>2018</b> , 53, 65-72	5.6	38
140	The development and validation of the Unidimensional Fatigue Impact Scale (U-FIS). <i>Multiple Sclerosis Journal</i> , <b>2009</b> , 15, 1228-38	5	38
139	Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population. <i>Value in Health</i> , <b>2009</b> , 12, 657-65	3.3	38
138	Outcomes of incident mild cognitive impairment in relation to case definition. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2005</b> , 76, 1175-7	5.5	37
137	Long-term Cognitive Outcomes in Patients With Pediatric-Onset vs Adult-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , <b>2019</b> , 76, 1028-1034	17.2	36
136	Screening for cognitive impairment in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 1371-7	4.1	36
135	The Prevalence and Risk Factors of Undiagnosed Depression and Anxiety Disorders Among Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 1674-1680	4.5	35
134	Five years before multiple sclerosis onset: Phenotyping the prodrome. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 1092-1101	5	35
133	Social anxiety in a multiple sclerosis clinic population. <i>Multiple Sclerosis Journal</i> , <b>2009</b> , 15, 393-8	5	35
132	Preclinical vascular cognitive impairment and Alzheimer disease: neuropsychological test performance 5 years before diagnosis. <i>Stroke</i> , <b>2007</b> , 38, 1148-53	6.7	35
131	Orienting to Targets by Looking and Pointing: Parallels and Interactions in Ocular and Manual Performance. <i>Quarterly Journal of Experimental Psychology Section A: Human Experimental Psychology</i> , <b>1985</b> , 37, 315-338		34
130	Butyrylcholinesterase activity in multiple sclerosis neuropathology. <i>Chemico-Biological Interactions</i> , <b>2010</b> , 187, 425-31	5	33
129	Disclosure of the diagnosis of dementia. <i>Alzheimeris and Dementia</i> , <b>2007</b> , 3, 404-10	1.2	33
128	Improved detection of differential information-processing speed deficits between two disease-course types of multiple sclerosis.. <i>Neuropsychology</i> , <b>2001</b> , 15, 617-625	3.8	33
127	Patterns and health effects of caring for people with dementia: the impact of changing cognitive and residential status. <i>Gerontologist, The</i> , <b>2002</b> , 42, 643-52	5	33

126	Hospital-based psychiatric service utilization and morbidity in multiple sclerosis. <i>Canadian Journal of Neurological Sciences</i> , <b>1998</b> , 25, 230-5	1	33
125	Assessing the ADL functioning of persons with Alzheimer's disease: comparison of family informants ratings and performance-based assessment findings. <i>International Psychogeriatrics</i> , <b>1999</b> , 11, 399-409	3-4	33
124	The effects of instructions to subjects on the programming of visually directed reaching movements. <i>Journal of Motor Behavior</i> , <b>1989</b> , 21, 5-19	1.4	33
123	Orienting attention in aging and Parkinson's disease: distinguishing modes of control. <i>Journal of Clinical and Experimental Neuropsychology</i> , <b>2002</b> , 24, 951-67	2.1	32
122	Expression of the inhibitor of apoptosis protein family in multiple sclerosis reveals a potential immunomodulatory role during autoimmune mediated demyelination. <i>Multiple Sclerosis Journal</i> , <b>2008</b> , 14, 577-94	5	31
121	Differing trends in the incidence of vascular comorbidity in MS and the general population. <i>Neurology: Clinical Practice</i> , <b>2016</b> , 6, 120-128	1.7	31
120	Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 1130-1139	4.7	31
119	Comorbidity is associated with pain-related activity limitations in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2015</b> , 4, 470-476	4	30
118	The association of fatigue, pain, depression and anxiety with work and activity impairment in immune mediated inflammatory diseases. <i>PLoS ONE</i> , <b>2018</b> , 13, e0198975	3.7	30
117	The incidence and prevalence of thyroid disease do not differ in the multiple sclerosis and general populations: a validation study using administrative data. <i>Neuroepidemiology</i> , <b>2012</b> , 39, 135-42	5.4	30
116	The Canadian survey of health, lifestyle and ageing with multiple sclerosis: methodology and initial results. <i>BMJ Open</i> , <b>2014</b> , 4, e005718	3	29
115	Prevalence and incidence of ischemic heart disease in multiple sclerosis: A population-based validation study. <i>Multiple Sclerosis and Related Disorders</i> , <b>2013</b> , 2, 355-61	4	28
114	Reliability of regression-based normative data for the oral symbol digit modalities test: an evaluation of demographic influences, construct validity, and impairment classification rates in multiple sclerosis samples. <i>Clinical Neuropsychologist</i> , <b>2014</b> , 28, 281-99	4.4	27
113	Fatigue and Comorbidities in Multiple Sclerosis. <i>International Journal of MS Care</i> , <b>2016</b> , 18, 96-104	2.3	27
112	Estimating annual prevalence of depression and anxiety disorder in multiple sclerosis using administrative data. <i>BMC Research Notes</i> , <b>2017</b> , 10, 619	2.3	26
111	Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluation. <i>Multiple Sclerosis Journal</i> , <b>2009</b> , 15, 1286-94	5	26
110	The effect of the living situation on the severity of dementia at diagnosis. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2002</b> , 13, 40-5	2.6	26
109	Psychosocial and neurological predictors of mental health in multiple sclerosis patients. <i>Journal of Clinical Epidemiology</i> , <b>1996</b> , 49, 467-72	5.7	26

108	Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 588-596	5	25
107	MS incidence and prevalence in Africa, Asia, Australia and New Zealand: A systematic review. <i>Multiple Sclerosis and Related Disorders</i> , <b>2014</b> , 3, 48-60	4	25
106	International development of the patient-reported outcome indices for multiple sclerosis (PRIMUS). <i>Value in Health</i> , <b>2010</b> , 13, 946-51	3.3	25
105	Five-year outcomes for dementia defined solely by neuropsychological test performance. <i>Neuroepidemiology</i> , <b>2003</b> , 22, 172-8	5.4	25
104	Disability and frailty among elderly Canadians: a comparison of six surveys. <i>International Psychogeriatrics</i> , <b>2001</b> , 13 Supp 1, 159-67	3.4	25
103	Resting State BOLD Variability in Alzheimer's Disease: A Marker of Cognitive Decline or Cerebrovascular Status?. <i>Frontiers in Aging Neuroscience</i> , <b>2018</b> , 10, 39	5.3	24
102	An MRI brain atrophy and lesion index to assess the progression of structural changes in Alzheimer's disease, mild cognitive impairment, and normal aging: a follow-up study. <i>Journal of Alzheimer's Disease</i> , <b>2011</b> , 26 Suppl 3, 359-67	4.3	24
101	Intra-individual variability in information processing speed reflects white matter microstructure in multiple sclerosis. <i>NeuroImage: Clinical</i> , <b>2013</b> , 2, 894-902	5.3	21
100	A novel approach to estimate the minimally important difference for the Fatigue Impact Scale in multiple sclerosis patients. <i>Quality of Life Research</i> , <b>2010</b> , 19, 1349-58	3.7	21
99	Eye movements of human albinos. <i>Optometry and Vision Science</i> , <b>1984</b> , 61, 377-85	2.1	21
98	Adverse health behaviours are associated with depression and anxiety in multiple sclerosis: A prospective multisite study. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 685-93	5	20
97	Verbal repetition in patients with Alzheimer's disease who receive donepezil. <i>International Journal of Geriatric Psychiatry</i> , <b>2006</b> , 21, 426-31	3.9	20
96	Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates. <i>International Journal of Technology Assessment in Health Care</i> , <b>2000</b> , 16, 751-67	1.8	20
95	Diabetes and anxiety adversely affect cognition in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 27, 164-170	4	20
94	Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review. <i>Multiple Sclerosis and Related Disorders</i> , <b>2018</b> , 26, 124-156	4	20
93	Increased incidence and prevalence of psoriasis in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2017</b> , 13, 81-86	4	19
92	Indices of cognitive dysfunction in relapsing-remitting multiple sclerosis: intra-individual variability, processing speed, and attention network efficiency. <i>Journal of the International Neuropsychological Society</i> , <b>2013</b> , 19, 551-8	3.1	19
91	Diagnoses of Depression and Anxiety Versus Current Symptoms and Quality of Life in Multiple Sclerosis. <i>International Journal of MS Care</i> , <b>2018</b> , 20, 76-84	2.3	19

90	The incidence and prevalence of multiple sclerosis in Nova Scotia, Canada. <i>Canadian Journal of Neurological Sciences</i> , <b>2013</b> , 40, 824-31	1	19
89	Comparison of cognitive functions between people with silent and wild-type butyrylcholinesterase. <i>Journal of Neural Transmission</i> , <b>2007</b> , 114, 939-45	4.3	18
88	Apperceptive agnosia and face recognition. <i>Neurocase</i> , <b>2000</b> , 6, 403-414	0.8	18
87	Ethical guidelines of the Alzheimer Society of Canada. <i>Canadian Journal of Neurological Sciences</i> , <b>1998</b> , 25, 242-8	1	18
86	Repeated measurement of the attention components of patients with multiple sclerosis using the Attention Network Test-Interaction (ANT-I): stability, isolability, robustness, and reliability. <i>Journal of Neuroscience Methods</i> , <b>2013</b> , 216, 1-9	3	17
85	Altered functional connectivity and performance variability in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2014</b> , 20, 1453-63	5	17
84	Brain reactive autoantibodies and cognitive impairment in systemic lupus erythematosus. <i>Lupus</i> , <b>1994</b> , 3, 193-9	2.6	17
83	Effects of Psychiatric Comorbidity in Immune-Mediated Inflammatory Disease: Protocol for a Prospective Study. <i>JMIR Research Protocols</i> , <b>2018</b> , 7, e15	2	17
82	Neuropathologic burden and the degree of frailty in relation to global cognition and dementia. <i>Neurology</i> , <b>2020</b> , 95, e3269-e3279	6.5	17
81	Physical comorbidities increase the risk of psychiatric comorbidity in immune-mediated inflammatory disease. <i>General Hospital Psychiatry</i> , <b>2018</b> , 51, 71-78	5.6	16
80	Ethical considerations for decision making for treatment and research participation. <i>Alzheimeris and Dementia</i> , <b>2007</b> , 3, 411-7	1.2	16
79	Test-Retest Reliability of the Assessment of Motor and Process Skills in Elderly Adults. <i>Occupation Participation and Health</i> , <b>1999</b> , 19, 203-215		16
78	A Case Control Study of the Risks for Institutionalization of Elderly People in Nova Scotia*. <i>Canadian Journal on Aging</i> , <b>1994</b> , 13, 104-117	1.6	16
77	Screening Tools for Anxiety in People with Multiple Sclerosis: A Systematic Review. <i>International Journal of MS Care</i> , <b>2016</b> , 18, 273-281	2.3	16
76	Intra-individual Variability as a Measure of Information Processing Difficulties in Multiple Sclerosis. <i>International Journal of MS Care</i> , <b>2012</b> , 14, 77-83	2.3	15
75	Stability of intraindividual variability as a marker of neurologic dysfunction in relapsing remitting multiple sclerosis. <i>Journal of Clinical and Experimental Neuropsychology</i> , <b>2014</b> , 36, 455-63	2.1	14
74	International development of the Unidimensional Fatigue Impact Scale (U-FIS). <i>Value in Health</i> , <b>2010</b> , 13, 463-8	3.3	14
73	Physical comorbidities increase the risk of psychiatric comorbidity in multiple sclerosis. <i>Brain and Behavior</i> , <b>2016</b> , 6, e00493	3.4	14



72	Comorbidities Are Associated with Altered Health Services Use in Multiple Sclerosis: A Prospective Cohort Study. <i>Neuroepidemiology</i> , <b>2018</b> , 51, 1-10	5.4	14
71	Prodrome in relapsing-remitting and primary progressive multiple sclerosis. <i>European Journal of Neurology</i> , <b>2019</b> , 26, 1032-1036	6	13
70	Hand dexterity and direct disease related cost in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , <b>2014</b> , 341, 51-4	3.2	13
69	The incidence and prevalence of fibromyalgia are higher in multiple sclerosis than the general population: A population-based study. <i>Multiple Sclerosis and Related Disorders</i> , <b>2012</b> , 1, 162-7	4	13
68	Lipid-lowering agents and the risk of cognitive impairment that does not meet criteria for dementia, in relation to apolipoprotein E status. <i>Neuroepidemiology</i> , <b>2007</b> , 29, 201-7	5.4	13
67	APOE genotype, vascular risk factors, memory test performance and the five-year risk of vascular cognitive impairment or Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2005</b> , 20, 292-7	2.6	13
66	Blood-brain barrier leakage in systemic lupus erythematosus is associated with gray matter loss and cognitive impairment. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1580-1587	2.4	13
65	Lateralized microstructural changes in early-stage Parkinson's disease in anterior olfactory structures, but not in substantia nigra. <i>Journal of Neurology</i> , <b>2017</b> , 264, 1497-1505	5.5	12
64	Social vulnerability and prefrontal cortical function in elderly people: a report from the Canadian Study of Health and Aging. <i>International Psychogeriatrics</i> , <b>2011</b> , 23, 450-8	3.4	12
63	Prevalence of cognitive impairment and dementia as defined by neuropsychological test performance. <i>Neuroepidemiology</i> , <b>2000</b> , 19, 121-9	5.4	12
62	Tonic vibration reflexes and background force level. <i>Acta Astronautica</i> , <b>1992</b> , 26, 133-6	2.9	12
61	The Relationship Between Symptoms of Depression and Anxiety and Disease Activity in IBD Over Time. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, 1285-1293	4.5	12
60	Contribution of perceptual and lexical-semantic errors to the naming impairments in Alzheimer's disease. <i>Perceptual and Motor Skills</i> , <b>1991</b> , 73, 175-83	2.2	11
59	Fatigue, sleep disorders, anaemia and pain in the multiple sclerosis prodrome. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 290-302	5	11
58	Mining healthcare data for markers of the multiple sclerosis prodrome. <i>Multiple Sclerosis and Related Disorders</i> , <b>2018</b> , 25, 232-240	4	10
57	APOE genotype, memory test performance, and the risk of Alzheimer's disease in the Canadian Study of Health and Aging. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2003</b> , 15, 1-5	2.6	10
56	Drug therapy in multiple sclerosis: a study of Nova Scotia senior citizens. <i>Clinical Therapeutics</i> , <b>1996</b> , 18, 303-18; discussion 302	3.5	10
55	Chronic lung disease and multiple sclerosis: Incidence, prevalence, and temporal trends. <i>Multiple Sclerosis and Related Disorders</i> , <b>2016</b> , 8, 86-92	4	10

54	Conceptual reasoning as a mediator of verbal recall in patients with multiple sclerosis. <i>Journal of Clinical and Experimental Neuropsychology</i> , <b>1996</b> , 18, 211-9	2.1	9
53	Gender differences in information needs and preferences regarding depression among individuals with multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis. <i>Patient Education and Counseling</i> , <b>2019</b> , 102, 1722-1729	3.1	8
52	Factors associated with perceived need for mental health care in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2018</b> , 25, 179-185	4	8
51	Neuropsychological detection of cognitive impairment: inter-rater agreement and factors affecting clinical decision-making. <i>Journal of the International Neuropsychological Society</i> , <b>2006</b> , 12, 72-9	3.1	8
50	Cognitive screening in a population-based sample of community-living elderly: Effects of age and education on the construct of cognitive status. <i>International Journal of Geriatric Psychiatry</i> , <b>1995</b> , 10, 687-694	3.9	7
49	Pandemic Dementia Scarce Resource Allocation. <i>Canadian Geriatrics Journal</i> , <b>2020</b> , 23, 216-218	2.8	7
48	Information processing and magnetic resonance imaging indices of brain pathology in multiple sclerosis. <i>International Journal of MS Care</i> , <b>2012</b> , 14, 84-91	2.3	7
47	Validation of the PHQ-9 for Suicidal Ideation in Persons with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , <b>2018</b> , 24, 1641-1648	4.5	6
46	Cholinesterases in normal and Alzheimer's disease primary olfactory gyrus. <i>Neuropathology and Applied Neurobiology</i> , <b>2017</b> , 43, 571-583	5.2	6
45	Progressive anomia without semantic or phonological impairment. <i>Cortex</i> , <b>2007</b> , 43, 558-64	3.8	6
44	Contribution of Perceptual and Lexical-Semantic Errors to the Naming Impairments in Alzheimer's Disease		6
43	Spatial normalization of multiple sclerosis brain MRI data depends on analysis method and software package. <i>Magnetic Resonance Imaging</i> , <b>2020</b> , 68, 83-94	3.3	6
42	Interrogation of the Multiple Sclerosis Prodrome Using High-Dimensional Health Data. <i>Neuroepidemiology</i> , <b>2020</b> , 54, 140-147	5.4	5
41	Visual and Auditory fMRI Paradigms for Presurgical Language Mapping: Convergent Validity and Relationship to Individual Variables. <i>Neurology Research International</i> , <b>2019</b> , 2019, 6728120	1.7	5
40	Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records. <i>Neuroepidemiology</i> , <b>2017</b> , 48, 124-130	5.4	4
39	Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting. <i>Expert Review of Neurotherapeutics</i> , <b>2021</b> , 21, 131-140	4.3	4
38	Incidence of Adverse Psychiatric Events During Treatment of Inflammatory Bowel Disease With Biologic Therapies: A Systematic Review. <i>Crohn's &amp; Colitis</i> <b>360</b> , <b>2020</b> , 2, otz053	1.4	3
37	Identifying optic neuritis and transverse myelitis using administrative data. <i>Multiple Sclerosis and Related Disorders</i> , <b>2018</b> , 25, 258-264	4	3

36	Peripheral dysgraphia: dissociations of lowercase from uppercase letters and of print from cursive writing. <i>Cognitive and Behavioral Neurology</i> , <b>2014</b> , 27, 31-47	1.6	3
35	Social phobia in immune-mediated inflammatory diseases. <i>Journal of Psychosomatic Research</i> , <b>2020</b> , 128, 109890	4.1	3
34	Impact of Psychiatric Comorbidity on Health Care Use in Rheumatoid Arthritis: A Population-Based Study. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 90-99	4.7	3
33	Prevalence of Psychiatric Disorders is Increased Five Years before the Diagnosis in IBD. <i>Gastroenterology</i> , <b>2017</b> , 152, S973	13.3	2
32	Adjusting for differential misclassification in matched case-control studies utilizing health administrative data. <i>Statistics in Medicine</i> , <b>2019</b> , 38, 3669-3681	2.3	2
31	Higher health care use before a clinically isolated syndrome with or without subsequent MS. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 35, 42-49	4	2
30	Ethical considerations for the conduct of antidementia trials in Canada. <i>Canadian Journal of Neurological Sciences</i> , <b>2007</b> , 34 Suppl 1, S32-6	1	2
29	Screening for cognitive impairment in the elderly: Impact of physical function measures added to cognitive screening instruments. <i>Aging, Neuropsychology, and Cognition</i> , <b>1994</b> , 1, 261-270	2.1	2
28	A systematic review of the effects of cannabis on cognition in people with multiple sclerosis.. <i>Multiple Sclerosis and Related Disorders</i> , <b>2022</b> , 57, 103338	4	2
27	Anxiety and depression affect performance on the symbol digit modalities test over time in MS and other immune disorders. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 1284-1292	5	2
26	Uptake of influenza vaccination among persons with inflammatory bowel disease, multiple sclerosis or rheumatoid arthritis: a population-based matched cohort study. <i>CMAJ Open</i> , <b>2021</b> , 9, E510-E521	2.5	2
25	Cholinergic Neurons in Nucleus Subputaminalis in Primary Progressive Aphasia. <i>Canadian Journal of Neurological Sciences</i> , <b>2019</b> , 46, 174-183	1	2
24	Author response: Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders. <i>Neurology</i> , <b>2019</b> , 93, 1081-1082	6.5	2
23	MRI utilization during the diagnostic and post-diagnostic phases in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 28, 138-144	4	2
22	Performance of Regression-Based Norms for Cognitive Functioning of Persons With Multiple Sclerosis in an Independent Sample. <i>Frontiers in Neurology</i> , <b>2020</b> , 11, 621010	4.1	2
21	Predictors of chronic cerebrospinal venous insufficiency procedure use among older people with multiple sclerosis: a national case-control study. <i>BMC Health Services Research</i> , <b>2015</b> , 15, 161	2.9	1
20	The Halifax Mental Status Scale: Development of a new test of mental status for use with elderly clients.. <i>Psychological Assessment</i> , <b>1991</b> , 3, 162-167	5.3	1
19	Effect of mood and anxiety disorders on health care utilization in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 1411-1420	5	1

18	The association between childhood maltreatment and pain catastrophizing in individuals with immune-mediated inflammatory diseases. <i>Journal of Psychosomatic Research</i> , <b>2021</b> , 145, 110479	4.1	1
17	Response to: Correspondence on Blood-brain barrier leakage in systemic lupus erythematosus is associated with gray matter loss and cognitive impairment by Pamuk and Hasni. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	1
16	Clinicopathological correlations and cholinesterase expression in early-onset familial Alzheimer's disease with the presenilin 1 mutation, Leu235Pro. <i>Neurobiology of Aging</i> , <b>2021</b> , 103, 31-41	5.6	1
15	Comorbidity and persistence of disease-modifying therapy use in relapsing remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 56, 103249	4	1
14	Disease-modifying drugs for multiple sclerosis and subsequent health service use.. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211063403	5	1
13	Olfactory Function and Diffusion Tensor Imaging as Markers of Mild Cognitive Impairment in Early Stages of Parkinson's Disease. <i>Clinical EEG and Neuroscience</i> , <b>2021</b> , 15500594211058263	2.3	0
12	The Impact of Psychiatric Comorbidity on Health Care Utilization in Inflammatory Bowel Disease: A Population-based Study. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, 1462-1474	4.5	0
11	Clinical and neuropathological variability in the rare IVS10+14 tau mutation. <i>Neurobiology of Aging</i> , <b>2021</b> , 101, 298.e1-298.e10	5.6	0
10	Effect of comorbid mood and anxiety disorders on breast and cervical cancer screening in immune-mediated inflammatory disease. <i>PLoS ONE</i> , <b>2021</b> , 16, e0249809	3.7	0
9	Higher Framingham Risk Scores are associated with greater loss of brain volume over time in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 54, 103088	4	0
8	Use of Benzodiazepines and Z-Drugs in Multiple Sclerosis.. <i>Frontiers in Neurology</i> , <b>2022</b> , 13, 874724	4.1	0
7	Differing trends in the incidence of vascular comorbidity in MS and the general population. <i>Neurology: Clinical Practice</i> , <b>2016</b> , 6, 201-202	1.7	
6	Psychopathology, Neurodiagnostic Testing, and Imaging <b>2013</b> , 382-392		
5	Disconnection of language and memory in semantic dementia: a comparative and theoretical analysis. <i>Current Alzheimer Research</i> , <b>2005</b> , 2, 435-48	3	
4	Reply from the author.. <i>Canadian Journal of Neurological Sciences</i> , <b>1995</b> , 22, 75-75	1	
3	Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population.. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 794075	8.4	
2	Treatment of neuropsychiatric lupus <b>2015</b> , 1107-1111		
1	Emergency department use by persons with MS: A population-based descriptive study with a focus on infection-related visits.. <i>Multiple Sclerosis Journal</i> , <b>2022</b> , 13524585221078497	5	

